Oral Solid Dosage CDMO Market To Reach $77.06 Billion By 2033

Oral Solid Dosage CDMO Market Growth & Trends

The global oral solid dosage CDMO market size is expected to reach USD 77.06 billion by 2033, registering a CAGR of 6.58% from 2026 to 2033, according to a new report by Grand View Research, Inc. The increasing demand for outsourcing oral solid dosage manufacturing among pharmaceutical and biopharmaceutical companies has compelled contract development and manufacturing organizations (CDMO) to expand their manufacturing facilities to support the demand of pharmaceutical companies. These expansions are made across the globe to enhance their oral solid dosage industry penetration. Furthermore, the rising demand for generic drugs is a key factor for the market growth as there are increasing numbers of generics as OSD products.

The growing number of patients suffering from chronic and infectious diseases is key factor driving demand for novel therapeutics, thereby positively influencing overall industry progression. In addition, Booming geriatric population that are highly prone to chronic diseases and high adoption rate of OSD among this population further supporting the demand for OSD. Furthermore, another factor contributing to the market growth is adverse drug reactions to existing drugs, which have increased the demand for novel treatment options.

Ongoing technological advancements in the oral solid dosage CDMO market to enhance manufacturing efficiency, product quality, and regulatory compliance are positively influencing overall market growth potential. Continuous manufacturing assists seamless integration of numerous unit operations leading to streamlined production workflows and increased flexibility in manufacturing oral solid dosage forms. Moreover, innovations in techniques such as chromatography, spectroscopy, mass spectrometry, and dissolution testing enabled CDMOs to meet enhanced precision, sensitivity, & reliability in pharmaceutical analysis. Furthermore, the integration of automation, robotics, & data analytics streamlined analytical workflows, reduced turnaround times, and enhanced data integrity & compliance with regulatory standards such as Good Manufacturing Practices (GMP) & International Council for Harmonization (ICH) guidelines.

 Request a free sample copy or view report summary: Oral Solid Dosage CDMO Market Report

Oral Solid Dosage CDMO Market Report Highlights

• The OSD CDMO market is experiencing significant technological advancements, enhancing drug development and manufacturing processes

• In 2024, the tablet segment held the largest market share, accounting for a revenue share of 32.05%. The segment growth is driven by its broad applicability, diverse formulations, patient preference, and global acceptance.

• In 2024, controlled release held the largest revenue share due to improved patient compliance, enhanced efficacy and safety, and reduced frequency of administration are some significant factors expected to drive the segment during the forecast period.

• The low-potency drugs segment dominated the market in 2024. Increasing requirements for low-potency oral solid dosage manufacturing processes and growing innovation of new drugs drive this segment.

• On the basis of the service segment, the contract development segment dominated the market in 2024. Segment growth is driven by increasing requirements for early-stage formulation, analytical method development

• The medium & small-sized companies segment dominated the global market in 2024 and is anticipated to witness the fastest growth over the forecast period.

• North America is projected to register a significant CAGR during the forecast period. This growth can be attributed to growing investments in R&D of new drugs by pharmaceutical companies

Oral Solid Dosage CDMO Market Segmentation

Grand View Research has segmented the global oral solid dosage CDMO market report based on product, mechanism, drug potency, service, end use, and region:

Oral Solid Dosage CDMO Product Outlook (Revenue, USD Million, 2021 - 2033)

• Tablets

  • Compressed Tablets

  • Orally Disintegrating Tablets (ODT)

  • Chewable Tablets

  • Bi-layer or Tri-layer Tablets

  • Sublingual or Buccal Tablets

  • Others

• Capsules

  • Hard Gelatin Capsules

  • Soft Gelatin Capsules

• Powders

• Granules

• Others

Oral Solid Dosage CDMO Mechanism Outlook (Revenue, USD Million, 2021 - 2033)

• Immediate Release

• Delayed Release

• Controlled Release

Oral Solid Dosage CDMO Drug Potency Outlook (Revenue, USD Million, 2021 - 2033)

• High Potent Drugs

• Moderate Potent Drugs

• Low Potent Drugs

Oral Solid Dosage CDMO Service Outlook (Revenue, USD Million, 2021 - 2033)

• Contract Development

• Contract Manufacturing

• Packaging and Labelling

• Regulatory Affairs

• Logistics & Storage

• Others

Oral Solid Dosage CDMO End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Large Size Companies

• Medium & Small Size Companies

• Others

Oral Solid Dosage CDMO Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Oman

  • Qatar

List of Key Players in Oral Solid Dosage CDMO Market

• Lonza

• Thermo Fisher Scientific Inc.

• Cambrex Corporation

• Catalent Inc.

• Siegrfried Holding AG

• Recipharm AB

• CordenPharma International

• Boehringer Ingelheim

• Piramal Pharma Solutions

• Aenova Group

• Almac Group

• Jubilant Pharmova Limited

• Delpharm

• AbbVie Contract Manufacturing

• Next Pharma AB

• Rubicon Research Pvt. Ltd.

• Quotient Sciences

• SPI Pharma

• DPT Laboratories Ltd.

• Alcami Corporation